ABSTRACT:
The stability of Raltegravir (RAL) was investigated under different stress conditions, including hydrolytic, oxidative, photolytic and thermal, as recommended by the ICH guidelines. Degradation was observed under alkaline hydrolytic condition. The major degradation products in alkaline degradation conditions were proposed. A simple, sensitive and specific HPLC method was developed for the quantification of RAL under forced degradation study. The separation employs aluminum backed silicagel-G F254 as stationary phase and mixture of Toluene: ethylacetate: methanol: acetic acid (8:1:1:0.1v/v/v/v) as a mobile phase. The detection wavelength of 299nm was selected for analysis. The method was validated, demonstrating to be accurate and precise (repeatability and intermediate precision levels) within the corresponding linear range of RAL (200-700ng/spot;r= 0.9923, n=5).Limits of detection and limit of quantification were determined to be 33.99ng/spot and 103.01ng/spot respectively. Peak purity indices (>0.9997) and satisfactory resolution between RAL and its degradation products established the specificity of the determinations. The kinetics of the degradation of RAL in alkaline medium was studied, determining as zero order kinetics with energy of activation to be 5.99 Kcal/mol.
Cite this article:
Patidar Shubham, Vengurlekar Sudha, Jain Sachin Kumar. Development and Validation of Analytical Method of Raltegravir, An Antiviral Drug. Asian Journal of Pharmaceutical Analysis. 2024; 14(1):21-5. doi: 10.52711/2231-5675.2024.00005
Cite(Electronic):
Patidar Shubham, Vengurlekar Sudha, Jain Sachin Kumar. Development and Validation of Analytical Method of Raltegravir, An Antiviral Drug. Asian Journal of Pharmaceutical Analysis. 2024; 14(1):21-5. doi: 10.52711/2231-5675.2024.00005 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2024-14-1-5
REFERENCES:
1. White DE, Frank J.Medical Virology. 4th ed. California USA: Academic Press. 1994; 235-296.
2. HIV AIDS. Treatment and Prevention in India: Modeling the costs and consequence; The World Bank: Washington D.C, India Art Report. 2004.
3. Erik Declercq. Antiviral durgs in current clinical use. Journal of Clinical Virology. 2004; 30: 115-133.
4. Sethi PD. HPTLC Quantitative Analysis of Pharmaceutical Formulations.2nd ed. New Delhi: CBS Publication and Distributors. 2001;48-55.
5. Hamilton RJ, Sevell PA. Introduction to HPLC. 2nd ed. London: Chapman and Hall. 1982.
6. Munson JW. High-Performance Liquid Chromatography: Theory, Instrumentation, and Pharmaceutical Applications. New York: Marcel Dekker Inc. 2001; 665-668.
7. Sharma J, Fried B. Hand Book of Thin Layer Chromatography. 3rd ed. New York: Marcel Dekker Inc. 2003; 767-805.
8. Sethi PD. HPTLC Quantitative Analysis of Pharmaceutical Formulations. 1st ed. New Delhi: CBS Publication and Distributors. 1996; 4-28.
9. Cartenson JT, Swarbirck J. Solution Kinetics- Drug Stability Principles and Practice. 2nd ed. New York: Marcel Dekker Inc. 1995.
10. Q1A (R2): Stability Testing of New Drugs and Products. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline. 2003.